Mr. Joe Hsueh has served as an independent director of Apollomics since 2025. He brings to the Board over 25 years of experience in operations, finance, and business development across the biopharmaceutical and venture capital industries in Taiwan, China, and the United States.

Mr. Hsueh is currently the President of Anbogen Therapeutics, where he leads finance operations and business development, leveraging his expertise in venture capital and the pharmaceutical sector. Previously, he was the Chief Operating Officer and co-founder of ACT Genomics, where he spearheaded finance operations, sales, marketing, and business development teams to drive strategic growth opportunities.

Earlier in his career, Mr. Hsueh held senior positions at TaiGen Biotechnology in Taiwan, where he successfully led the company through three rounds of financing, co-managed another, and secured a total of USD $114 million within seven years. He also executed an out-licensing agreement and played a key role in expanding business networks within the global pharmaceutical industry. Prior to TaiGen, he worked at Chengxin VC, where he led fundraising efforts for six companies across the U.S. and Taiwan.

Mr. Hsueh holds an MBA from Fairleigh Dickinson University in the United States and a B.A. in Microbiology from Soochow University in Taiwan.